AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01403883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Psychological \& enterostomal therapy clinics on demand only
Study NCT01403883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimal care (Psychological and enterostomal therapy clinics)
Description: Psychological clinics at D-45, D0, D45, D60, D90 enterostomal therapy clinics at D-45, D0, D45, D60
Study NCT02630745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate periodontal surgery
Description: Treatment involves immediate surgical periodontal therapy in form of open flap debridement after non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in concurrent endodontic periodontal lesions with communication .
Study NCT02630745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed periodontal surgery
Description: Treatment involves surgical periodontal therapy after 3 months of non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in the form of open flap debridement in concurrent endodontic periodontal lesions with communication .
Study NCT04033133 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Subjects will get tDCS at intensities of 0, 1, 2, 3, and 4 mA.
Study NCT04033133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Subjects will get tDCS at intensities of 0, 1, 2, 3, and 4 mA.
Study NCT02272348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training course to functional insulin therapy
Description: Carbohydrate counting, carbohydrate/insulin ratio, sensitivity to insulin factor
Study NCT02272348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual diabetes management.
Study NCT01698320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDPI
Description: Placebo MDPI (multi-dose dry powder inhaler) to match the active intervention.
Study NCT01698320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol MDPI
Description: Albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation.
Study NCT01698320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol MDPI
Description: Albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation.
Study NCT04028583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PIM-Check
Description: In the PIM-Check group, a medication review will be conducted using PIM-Check within 72 hours of patient's admittance to the unit. The physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
Study NCT04028583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STOPP/START
Description: In the STOPP/START group, medication lists will be analyzed within 72 hours of patient's admittance and optimized according to STOPP/START criteria. The second physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
Study NCT04405206 — intervention group
Intervention type: DRUG
Intervention: Oxaliplatin
Description: OXA 130mg/m2
Study NCT04405206 — intervention group
Intervention type: DRUG
Intervention: Capecitabine
Description: Cape 1000mg/m2
Study NCT04405206 — intervention group
Intervention type: RADIATION
Intervention: intensity modulated radiotherapy
Description: IMRT 50.4Gy/22f
Study NCT04405206 — intervention group
Intervention type: PROCEDURE
Intervention: DRE-Endoscopy-MRI-CEA
Description: examination process in follow up
Study NCT01659827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1.25cc AmnioFix
Description: Injection of 1.25cc of AmnioFix Injectable
Study NCT01659827 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Injection of 1.25cc of Saline
Study NCT00975182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Oral repeating dose
Study NCT00975182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib HCl
Description: Oral repeating dose
Study NCT01283464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retinol
Description: 1.0% cream
Study NCT01283464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin
Description: 0.02% cream
Study NCT00553839 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ketamine hydrochloride
Description: Open label pharmacokinetic study to be conducted in infants and children presenting for medical procedures (eg., surgery or cardiac catheterization). After the start of the procedure, a 0.5 cc preload blood sample (T0) will be drawn from an IV line. Then a 2 mg/kg IV bolus of Ketamine will be administered over 5 minutes. Timed 0.5 ml blood samples will be drawn at the following intervals: 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, 360 and 720 minutes after bolus.
Study NCT02045069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 days Ivermectin
Description: 200-400 µg/kg once daily for 2 days and placebo once daily at D3
Study NCT02045069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 days Ivermectin
Description: 200 -400 µg/kg once daily for 3 days
Study NCT02045069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 3 days
Study NCT01764360 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: KS structured clinical care training
Description: Eight primary care sites in Zimbabwe will receive structured training for diagnosis and treatment of Kaposi sarcoma (KS)
Study NCT01422564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal on Metal Hip System
Description: Total hip arthroplasty with a metal on metal component system
Study NCT01422564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Highly Cross Linked Polyethylene cup System
Description: Total hip arthroplasty with Highly Cross Linked Polyethylene cup System
Study NCT03299660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/Kg every 2 weeks for 4 cycles post LCCRT
Study NCT03299660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Fluorouracil
Description: 5FU continuous infusion 225mg/m2/day during radiotherapy
Study NCT03299660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine Pill
Description: Can be administered in place of 5FU infusion. Dose = 825 mg/m2 twice a day on each day of radiotherapy
Study NCT03299660 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 50.4 Gy in 28 fractions delivered over 5.5 weeks as 5 fractions/week
Study NCT03299660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical resection of tumour mass post radiotherapy and chemotherapy
Study NCT02606916 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SMART
Description: Once-daily simultaneous modulated accelerated radiotherapy(64Gy/30f )
Study NCT02606916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDP
Description: DDP(25 mg/m2.qw) for six weeks.
Study NCT02606916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1(40 mg/m2.Bid .po) on D1-14，D22-35 during radiotherapy
Study NCT01099150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark chocolate enriched in flavan-3-ols and procyanidins
Description: Acute consumption (within 15 minutes) of 60 g of chocolate containing \~900 mg of total flavan-3-ols and procyanidins.
Study NCT01099150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard dark chocolate
Description: Acute consumption (within 15 minutes) of 60 g of chocolate containing \~400 mg total flavan-3-ols and procyanidins.
Study NCT01099150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White chocolate
Description: Acute consumption (within 15 minutes) of 60 g of white chocolate containing no flavan-3-ols and procyanidins.
Study NCT01369147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral Nutrition
Description: The PN dose will be written for each 24-hr period taking into account any kilocalories (kcal) provided as part of standard of care from propofol, clevidipine, dextrose-containing IV fluid exceeding 500 mL/day, and enteral feedings.
Study NCT01369147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral Nutrition
Description: The PN dose will be written for each 24-hr period taking into account any kilocalories (kcal) provided as part of standard of care from propofol, clevidipine, dextrose-containing IV fluid exceeding 500 mL/day, and enteral feedings.
Study NCT01369147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in the sedative propofol (1.1 kcal/mL).
Study NCT01369147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in the sedative propofol (1.1 kcal/mL).
Study NCT01369147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevidipine
Description: The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in clevidipine (2 kcal/mL).
Study NCT01369147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clevidipine
Description: The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in clevidipine (2 kcal/mL).
Study NCT01369147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose-containing IV Fluids
Description: The PN dose will be written for each 24-hr period taking into account calories provided from dextrose-containing IV fluid orders exceeding 500 mL/day.
Study NCT01369147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose-containing IV Fluids
Description: The PN dose will be written for each 24-hr period taking into account calories provided from dextrose-containing IV fluid orders exceeding 500 mL/day.
Study NCT01369147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteral feeding
Description: Enteral nutrition is caloric intake through the gastrointestinal (GI) tract via food consumed through the mouth or a feeding tube delivering nutrition directly to the stomach or small intestines. The PN dose will be written for each 24-hr period taking into account calories provided from any enteral feedings.
Study NCT01369147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteral feeding
Description: Enteral nutrition is caloric intake through the gastrointestinal (GI) tract via food consumed through the mouth or a feeding tube delivering nutrition directly to the stomach or small intestines. The PN dose will be written for each 24-hr period taking into account calories provided from any enteral feedings.
Study NCT02351609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Intervention patients will be introduced to the patient navigator either in person or by telephone. The intervention patients will receive navigation from one of two trained navigators, based centrally in the Section of General Internal Medicine. The purpose of the patient navigation interactions is to 1) connect patients to existing yet underutilized smoking cessation resources and 2) increase patient commitment to follow through with existing treatment services.~Financial incentives: $250 for biochemically confirmed abstinence within six months after study enrollment, and $500 for biochemically confirmed abstinence for an additional six months after the initial cessation.
Study NCT02351609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Traditional Care control
Description: List of smoking cessation resources and educational brochure.
Study NCT04430556 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sertraline
Description: Sertraline will be started in all patients, unless it is contraindicated, in this case, Escitalopram will be indicated.
Study NCT04722068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinetics test
Description: Subjects will participate in two study visits to evaluate lipoprotein kinetics before and after administration of evinacumab.
Study NCT04145180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: 40 minutes of physiotherapy, based on manual therapy sessions over 6 weeks. Three times a week.
Study NCT00637312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Artificial Disc (Advent™ Cervical Disc)
Description: Advent™ Cervical Disc
Study NCT00637312 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hallmark™ Anterior Cervical Plate System
Description: Hallmark™ Anterior Cervical Plate System with AlloQuent Structural Allograft (corticocancellous allograft bone)
Study NCT03357523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnilux new-U (Red LED)
Description: The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Red LED) light source, while the right wrist will not be illuminated
Study NCT03357523 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnilux new-U (Near infrared LED)
Description: The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Near infrared LED) light source, while the right wrist will not be illuminated
Study NCT03357523 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RESPeRATE
Description: The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm
Study NCT03357523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESPeRATE
Description: The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm
Study NCT03357523 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heating bag
Description: Applying a standard 10X13 \[cm\] heating bag on the surface of the hand at 43-45 degree Celsius for 10 seconds
Study NCT03357523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heating bag
Description: Applying a standard 10X13 \[cm\] heating bag on the surface of the hand at 43-45 degree Celsius for 10 seconds
Study NCT01493674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid
Description: two 5-mg tablets of folic acid
Study NCT02146014 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.~In the placebo group the current will be off.
Study NCT02146014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.
Study NCT00925951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wet Cupping
Description: Wet cupping (Seongho trade \& company, Korea) will be practiced at two selected points (among the 6 acupoints, left or right BL23, BL24, BL25)
Study NCT00925951 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Acetaminophen
Description: Acetaminophen 500 mg tablets will be offered to both of the wet cupping group and waiting group for relieving severe pain.
Study NCT00925951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 500 mg tablets will be offered to both of the wet cupping group and waiting group for relieving severe pain.
Study NCT03693638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: 2,5 ml total anesthetic drug dose were given with 0.2 ml/second rate, and subjects were asked to remain sitted for 90 seconds
Study NCT03693638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: 1,5 ml of total anesthetic drug dose followed by 1 ml remaining dose after 90 s interval were given
Study NCT00772876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1446A-05
Description: P1446A-05 capsules will be given once daily for 28 days in each 28 day cycle for 4 such cycles. The starting dose, for first cohort will be 75 mg once daily. Subsequent cohorts of patients will receive higher doses till the recommended phase II dose is identified.
Study NCT00932048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 10mg once daily for 12 weeks
Study NCT01585051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25(OH) vitamin D
Description: 300 000 U intramuscularly, one dosage, in subjects with 25 (OH) vit D levels below 80 nmol/L, another dosage of 150 000 U after 3 months if 25(OH)vit D levels continue to be below 80 nmol/L.
Study NCT01585051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % NaCl
Description: 1 ml of 0.9 % of NaCl at the beginning and 0.5 ml of 0.9 % NaCl after three months
Study NCT04394780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cooling
Description: First, patients underwent peritoneal dialysis (PD) at 37 C (standard temperature) and then patients underwent PD cooling. After each PD session, the patient had a CT scan for the study team to study myocardial perfusion at rest and after introduction of a pharmacological stressor.
Study NCT02767011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-Health Electronic Monitoring (THEM)
Description: Patients in the intervention group (THEM) will receive a tablet computer and home monitoring medical devices with sensors to transmit the information to a central website that will be monitored by care managers. Medical devices will include weight scales, blood pressure cuffs and blood glucometers. Clinical care mangers will remotely monitor the patients and all electronic readings. Clinical care managers will call or send text messages to the patients based on alerts generated by the tele-health monitoring system.
Study NCT01850238 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AADvac1
Description: AADvac1 is intended as an active vaccination for disease-modifying treatment of Alzheimer's disease.
Study NCT01850238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains the same buffer and adjuvant as AADvac1, but lacks the API.
Study NCT04446169 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV 2 RNA PCR Urine
Description: Search for SARS-CoV 2 RNA in urine through PCR
Study NCT04446169 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV 2 RNA PCR Semen
Description: Search for SARS-CoV 2 RNA in Semen through PCR
Study NCT04446169 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Semen Qualitative Analysis
Description: Search for Semen Alterations in patients with past SARS-CoV 2 infection
Study NCT02399982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CBT-GSH
Description: The treatment will be based on Overcoming Binge Eating. The treatment is divided into a user-friendly section on binge eating and a six-step self-help program. The first session will last 60 min, with each subsequent section lasting 20-25 minutes in length. Sessions are weekly over 3 months. Working with the therapist, participants will use the self-help guide to develop regular and moderate eating using selfmonitoring, problem solving, and other CBT techniques.
Study NCT02399982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT-GSH
Description: The treatment will be based on Overcoming Binge Eating. The treatment is divided into a user-friendly section on binge eating and a six-step self-help program. The first session will last 60 min, with each subsequent section lasting 20-25 minutes in length. Sessions are weekly over 3 months. Working with the therapist, participants will use the self-help guide to develop regular and moderate eating using selfmonitoring, problem solving, and other CBT techniques.
Study NCT02399982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noom Monitor
Description: This treatment will be exactly the same as CBT-GSH with the exception that all self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session. Therapists will receive weekly letter grades regarding each patient based on weekly level of OBEs/Purging, treatment adherence, and weekly weighing.
Study NCT04446169 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IIEF-5 questionnaire
Description: IIEF-5 assessment in patients with past SARS-CoV 2 infection
Study NCT03184519 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test
Description: Instead of one blood sample, patients will have three blood analyses to predict pregnancy earlier after the embryo transfer.